SRDX vs. OFIX, ANGO, ARAY, CTSO, ATRC, ANIK, PLSE, SKIN, NPCE, and TCMD
Should you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include Orthofix Medical (OFIX), AngioDynamics (ANGO), Accuray (ARAY), Cytosorbents (CTSO), AtriCure (ATRC), Anika Therapeutics (ANIK), Pulse Biosciences (PLSE), Beauty Health (SKIN), NeuroPace (NPCE), and Tactile Systems Technology (TCMD). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
Orthofix Medical received 74 more outperform votes than Surmodics when rated by MarketBeat users. However, 67.00% of users gave Surmodics an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
Surmodics has a net margin of 3.99% compared to Surmodics' net margin of -20.28%. Orthofix Medical's return on equity of 8.06% beat Surmodics' return on equity.
Surmodics has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.
89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 96.6% of Surmodics shares are owned by institutional investors. 4.7% of Orthofix Medical shares are owned by insiders. Comparatively, 8.9% of Surmodics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Orthofix Medical had 4 more articles in the media than Surmodics. MarketBeat recorded 6 mentions for Orthofix Medical and 2 mentions for Surmodics. Orthofix Medical's average media sentiment score of 0.18 beat Surmodics' score of 0.12 indicating that Surmodics is being referred to more favorably in the news media.
Orthofix Medical presently has a consensus target price of $15.50, indicating a potential upside of 19.32%. Surmodics has a consensus target price of $59.00, indicating a potential upside of 125.45%. Given Orthofix Medical's stronger consensus rating and higher probable upside, analysts plainly believe Surmodics is more favorable than Orthofix Medical.
Orthofix Medical has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Summary
Surmodics beats Orthofix Medical on 14 of the 18 factors compared between the two stocks.
Get Surmodics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Surmodics Competitors List
Related Companies and Tools
